Please assess the completion status of the following clinical trial:

Trial Title: Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participation of patients in simultaneous diagnostic and comprehensive therapeutical trials for certain entities is allowed.~* Patients 18-60 years of age;~* Patients suffering from one of the following diseases:~  * AML: 1st complete remission (CR1) or beyond 1st remission (CR2, CR3), in relapse, not in remission (primary refractory, induction failure);~ * ALL: 1st complete remission (CR1) or beyond 1st remission (CR2, CR3), in relapse, not in remission (primary refractory, induction failure);~ * MDS, if transplantation is medically indicated: RA (with poor risk factors as classified by the International Prognostic Scoring System of MDS), RARS, RAEB, RAEB-t, CMML;~ * CML: beyond 1st chronic phase (CP1): accelerated phase, blast crisis, chronic phase (CP2, CP3);~ * OMF, if transplantation is medically indicated: Osteomyelofibrosis;~* Patients designated to undergo allogeneic bone marrow transplantation or allogeneic peripheral blood stem cell transplantation;~* Patients with a HLA-A, -B (DNA-based, 2 digits), HLA-DRB1, -DQB1 (DNA-based 4 digits) matched (8 out of 8 alleles) unrelated donor; serological typing is not required~* Patients with a Karnofsky Performance Score (KPS): \> 60%;~* Patients who underwent all obligatory screening examinations (special examinations within the last 4 weeks);~* Patients who have given their written informed consent to participate in the study.~Exclusion Criteria:~* Patients with significant cardiac (e.g. ejection fraction \<50%), pulmonary (e.g. FEV1 \<50%), renal (e.g. creatinine \> 1.5 mg/dl), metabolic (e.g. bilirubin \> 2.0 mg/dl) and/or CNS disease, currently uncontrolled by treatment, which may interfere with the completion of the study;~* Patients with any bacterial, viral, or fungal infections not under adequate antimicrobial control;~* Patients who are known to have serum hepatitis or who are carriers of the Hepatitis B surface antigen (HBs-Ag), or Hepatitis C antibody, or who are known to have a positive result to the test of HIV antibodies;~* Patients with any additional concurrent or previous malignant disease;~* Patients with known hypersensitivity to rabbit immunoglobulin antibodies in past patient history or with known allergy to any substance chemically related to the study medication;~* Pregnant (β-HCG test) or lactating women;~* Patients who formerly underwent transplantation including previous autologous transplants;~* Patients who cannot communicate reliably with the investigator or who are not likely to cope with the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ATG-F (Type: EXPERIMENTAL): ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)~cyclosporine A (target trough level \> 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11
- non-ATG-F (Type: NO_INTERVENTION): cyclosporine A (target trough level \> 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11

Based on this trial design, predict the completion outcome and termination type (if applicable).